ARCA Biopharma Inc logo

ABIO - ARCA Biopharma Inc Share Price

$4.21 -0.2  -4.1%

Last Trade - 26/02/21

Sector
Healthcare
Size
Micro Cap
Market Cap £28.2m
Enterprise Value £-8.51m
Revenue £n/a
Position in Universe 5654th / 6715
Bullish
Bearish
Unlock ABIO Revenue
Momentum
Relative Strength (%)
1m -1.56%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -80.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2014 2015 2016 2017 2018 2019 2020E 2021E CAGR / Avg
0.000 0.000 0.000 0.000 0.000 0.000
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the nine months ended 30 September 2020, ArcaBiopharma Inc revenues was not reported. Net loss increased8% to $4.6M. Higher net loss reflects Other -Research anddevelopment increase of 27% to $1.8M (expense), Interestand other income decrease of 80% to $27K (income), RentalExpense increase of 40% to $73K (expense). Basic Earningsper Share excluding Extraordinary Items increased from-$3.75 to -$1.88.
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

ABIO Revenue Unlock ABIO Revenue

Net Income

ABIO Net Income Unlock ABIO Revenue

Normalised EPS

ABIO Normalised EPS Unlock ABIO Revenue

PE Ratio Range

ABIO PE Ratio Range Unlock ABIO Revenue

Dividend Yield Range

ABIO Dividend Yield Range Unlock ABIO Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
ABIO EPS Forecasts Unlock ABIO Revenue
Profile Summary

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.

Directors
Last Annual December 31st, 2019
Last Interim September 30th, 2020
Incorporated March 16, 2004
Public Since July 21, 2000
No. of Shareholders: 13
No. of Employees: 9
Sector Healthcare
Industry Pharmaceuticals
Index Nasdaq Composite ,
Exchange NASDAQ Capital Market
Shares in Issue 9,321,470
Free Float (0.0%)
Eligible for
ISAs
SIPPs
ABIO Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for ABIO
Upcoming Events for ABIO
Frequently Asked Questions for ARCA Biopharma Inc
What is the ARCA Biopharma Inc share price?

As of 26/02/21, shares in ARCA Biopharma Inc are trading at $4.21, giving the company a market capitalisation of £28.2m. This share price information is delayed by 15 minutes.

How has the ARCA Biopharma Inc share price performed this year?

Shares in ARCA Biopharma Inc are currently trading at $4.21 and the price has moved by 29.34% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the ARCA Biopharma Inc price has moved by -0.22% over the past year.

What are the analyst and broker recommendations for ARCA Biopharma Inc?

Of the analysts with advisory recommendations for ARCA Biopharma Inc, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for ARCA Biopharma Inc is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will ARCA Biopharma Inc next release its financial results?

ARCA Biopharma Inc is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-09-30
What is the ARCA Biopharma Inc dividend yield?

ARCA Biopharma Inc does not currently pay a dividend.

Does ARCA Biopharma Inc pay a dividend?

ARCA Biopharma Inc does not currently pay a dividend.

When does ARCA Biopharma Inc next pay dividends?

ARCA Biopharma Inc does not currently pay a dividend.

How do I buy ARCA Biopharma Inc shares?

To buy shares in ARCA Biopharma Inc you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of ARCA Biopharma Inc?

Shares in ARCA Biopharma Inc are currently trading at $4.21, giving the company a market capitalisation of £28.2m.

Where are ARCA Biopharma Inc shares listed? Where are ARCA Biopharma Inc shares listed?

Here are the trading details for ARCA Biopharma Inc:

Country of listing: United States
Exchange: NAQ
Ticker Symbol: ABIO
What kind of share is ARCA Biopharma Inc?

Based on an overall assessment of its quality, value and momentum, ARCA Biopharma Inc is currently classified as a Style Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a ARCA Biopharma Inc share price forecast 2021?

Shares in ARCA Biopharma Inc are currently priced at $4.21. At that level they are trading at 66.27% discount to the analyst consensus target price of 0.00.

Analysts covering ARCA Biopharma Inc currently have a consensus Earnings Per Share (EPS) forecast of -9.59 for the next financial year.

How can I tell whether the ARCA Biopharma Inc share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like ARCA Biopharma Inc. Over the past six months, the relative strength of its shares against the market has been -22.88%. At the current price of $4.21, shares in ARCA Biopharma Inc are trading at -19.97% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the ARCA Biopharma Inc PE Ratio?

We were not able to find PE ratio data for ARCA Biopharma Inc.

Who are the key directors of ARCA Biopharma Inc?

ARCA Biopharma Inc's management team is headed by:

Michael Bristow - CEO
Linda Grais - LED
Christopher Ozeroff - SVP
Raymond Woosley - DRC
Robert Conway - CHM
Daniel Mitchell - DRC
Brian Selby - CAO
Thomas Keuer - COO
Anders Hove - DRC
Who are the major shareholders of ARCA Biopharma Inc?

Here are the top five shareholders of ARCA Biopharma Inc based on the size of their shareholding:

BlackRock Institutional Trust Company, N.A. Investment Advisor
Percentage owned: 3.08% (287k shares)
Renaissance Technologies LLC Hedge Fund
Percentage owned: 2.2% (206k shares)
Vanguard Extended Market Index Fund Mutual Fund
Percentage owned: 0.99% (92.5k shares)
The Vanguard Group, Inc. Investment Advisor/Hedge Fund
Percentage owned: 0.94% (87.6k shares)
GSA Capital Partners LLP Hedge Fund
Percentage owned: 0.49% (46.1k shares)
Similar to ABIO
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.